Clinical evidence that a dysregulated master neural network modulator may aid in diagnosing schizophrenia.
biomarker
blood test
collapsin response mediator protein-2 (CRMP2)
cytoskeleton
dendritic morphology
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
03 08 2021
03 08 2021
Historique:
entrez:
31
7
2021
pubmed:
1
8
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
There are no validated biomarkers for schizophrenia (SCZ), a disorder linked to neural network dysfunction. We demonstrate that collapsin response mediator protein-2 (CRMP2), a master regulator of cytoskeleton and, hence, neural circuitry, may form the basis for a biomarker because its activity is uniquely imbalanced in SCZ patients. CRMP2's activity depends upon its phosphorylation state. While an equilibrium between inactive (phosphorylated) and active (nonphosphorylated) CRMP2 is present in unaffected individuals, we show that SCZ patients are characterized by excess active CRMP2. We examined CRMP2 levels first in postmortem brains (correlated with neuronal morphometrics) and then, because CRMP2 is expressed in lymphocytes as well, in the peripheral blood of SCZ patients versus age-matched unaffected controls. In the brains and, more starkly, in the lymphocytes of SCZ patients <40 y old, we observed that nonphosphorylated CRMP2 was higher than in controls, while phosphorylated CRMP2 remained unchanged from control. In the brain, these changes were associated with dendritic structural abnormalities. The abundance of active CRMP2 with insufficient opposing inactive p-CRMP2 yielded a unique lowering of the p-CRMP2:CRMP2 ratio in SCZ patients, implying a disruption in the normal equilibrium between active and inactive CRMP2. These clinical data suggest that measuring CRMP2 and p-CRMP2 in peripheral blood might reflect intracerebral processes and suggest a rapid, minimally invasive, sensitive, and specific adjunctive diagnostic aid for early SCZ: increased CRMP2 or a decreased p-CRMP2:CRMP2 ratio may help cinch the diagnosis in a newly presenting young patient suspected of SCZ (versus such mimics as mania in bipolar disorder, where the ratio is high).
Identifiants
pubmed: 34330827
pii: 2100032118
doi: 10.1073/pnas.2100032118
pmc: PMC8346854
pii:
doi:
Substances chimiques
Biomarkers
0
Intercellular Signaling Peptides and Proteins
0
Nerve Tissue Proteins
0
collapsin response mediator protein-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIMH NIH HHS
ID : K08 MH087640
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH051290
Pays : United States
Organisme : NIMH NIH HHS
ID : RC2 MH090011
Pays : United States
Informations de copyright
Copyright © 2021 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Nat Med. 2011 Jun 05;17(7):822-9
pubmed: 21642979
Nature. 1995 Aug 10;376(6540):509-14
pubmed: 7637782
J Neurochem. 2004 Nov;91(3):716-36
pubmed: 15485501
Am J Med Genet B Neuropsychiatr Genet. 2010 Jun 5;153B(4):919-36
pubmed: 20127885
J Neurobiol. 2004 Jan;58(1):34-47
pubmed: 14598368
Nat Commun. 2014 Oct 31;5:5325
pubmed: 25358863
Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):559-76
pubmed: 15093964
Hum Mol Genet. 2012 Oct 15;21(20):4406-18
pubmed: 22798627
Mol Neurobiol. 2012 Apr;45(2):234-46
pubmed: 22351471
Mol Psychiatry. 2009 Aug;14(8):786-95
pubmed: 19223858
Science. 2018 Jun 22;360(6395):
pubmed: 29930110
Nat Genet. 2013 Oct;45(10):1150-9
pubmed: 23974872
Transl Psychiatry. 2020 Feb 24;10(1):76
pubmed: 32094324
Genes Cells. 2016 Sep;21(9):994-1005
pubmed: 27480924
Front Behav Neurosci. 2013 Dec 27;7:216
pubmed: 24409129
Arch Gen Psychiatry. 2000 Jan;57(1):65-73
pubmed: 10632234
Cardiovasc Psychiatry Neurol. 2009;2009:409562
pubmed: 20029620
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
J Biol Chem. 1998 Apr 17;273(16):9761-8
pubmed: 9545313
Dev Neurobiol. 2012 Dec;72(12):1528-40
pubmed: 22378692
Mol Psychiatry. 2015 Sep;20(9):1037-45
pubmed: 26077693
Proteomics Clin Appl. 2015 Oct;9(9-10):907-16
pubmed: 25821032
J Neurochem. 2013 Jul;126(2):165-82
pubmed: 23574039
Proteomics Clin Appl. 2015 Oct;9(9-10):817-31
pubmed: 25921334
Science. 2018 Feb 9;359(6376):693-697
pubmed: 29439242
J Neurochem. 2007 Nov;103(3):1132-44
pubmed: 17683481
Nature. 2009 Aug 6;460(7256):748-52
pubmed: 19571811
Genes Cells. 2005 Feb;10(2):165-79
pubmed: 15676027
Mol Psychiatry. 2012 Feb;17(2):142-53
pubmed: 22083728
Mol Psychiatry. 2015 Apr;20(4):424-32
pubmed: 25048004
Nat Commun. 2016 Jun 01;7:
pubmed: 27249678
Neuroscientist. 2014 Dec;20(6):589-98
pubmed: 24402611
JAMA Psychiatry. 2014 Dec 1;71(12):1323-31
pubmed: 25271938
Cell. 2018 Jun 14;173(7):1705-1715.e16
pubmed: 29906448
Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4462-E4471
pubmed: 28500272
Trends Neurosci. 2012 Jan;35(1):57-67
pubmed: 22154068
Int J Mol Med. 2015 Jun;35(6):1574-86
pubmed: 25847191
Genes Cells. 2016 Oct;21(10):1059-1079
pubmed: 27582038